Global R&D footprint Waterstone operates in Indianapolis with manufacturing in Wuhan and maintains an R&D center launched in 2010, signaling a capability to support global discovery-to-commercial programs and potential cross-border supply and collaboration opportunities.

Full-spectrum capability Offers a broad catalog of over 30,000 research products, custom synthesis, custom development and manufacturing, and cGMP APIs, presenting multiple entry points for pharma customers needing outsourcing, material sourcing, or scale-up capabilities.

Growth financing Secured a significant Series C funding round around $61 million in 2020, indicating investor confidence and potential for accelerated capacity expansion, new product initiatives, or regional market penetration.

Regulatory readiness Facilities meet ICH Q7 and US FDA cGMP guidelines, which can reassure potential clients about quality, compliance, and readiness for global production partnerships and audits.

Mid-market potential Current revenue bracket and employee size position Waterstone as a viable, scalable partner for mid-market pharmaceutical companies seeking reliable API supply, custom services, or strategic outsourcing without engaging with much larger incumbents.